Email Us
Call Us
AUSTIN, Texas – December 17, 2009 – Altogen Labs today detailed the genetic characterization and research applications of its validated T-47D xenograft model, a hormone-responsive platform for evaluating endocrine therapies and targeted treatments in ER-positive breast cancer.
The T-47D model is estrogen receptor-positive, progesterone receptor-positive, and HER2-negative, making it directly relevant to the study of endocrine therapy resistance. Its characterized mutation profile includes TP53 L194F, a loss-of-function alteration impairing the DNA damage response, and PIK3CA H1047R, an activating mutation driving PI3K/AKT signaling, proliferation, and therapy resistance. Additional alterations in RB1 and CDKN2A affect cell cycle regulation.
Published work includes a 2006 Cancer Research study by Hartman and colleagues using the T47D xenograft model to test the proliferative effects of estrogen receptor β, which has reported antiproliferative activity in contrast to the estrogen-mediated proliferation driven by ER-α.
Genetic characterization is what separates a useful model from a convenient one. A sponsor developing a PI3K inhibitor, a CDK4/6 inhibitor, or a next-generation endocrine agent needs to know the mutational context in which their compound is being tested – otherwise the result cannot be interpreted, let alone translated.
Altogen Labs provides this level of characterization across its validated collection, allowing sponsors to select models on the basis of driver genetics rather than availability. Complementary services include custom cell line engineering with stable overexpression or RNAi-mediated silencing, RT-PCR expression analysis, and automated capillary Western protein quantification.
About Altogen Labs
Altogen Labs is a preclinical CRO supporting drug development programs across oncology, pharmacology, toxicology, and translational research. The company has extensive experience with xenograft tumor models for preclinical efficacy studies and in vivo toxicology for safety evaluation, with a strong emphasis on high-quality, reproducible study execution and full client ownership of project-specific intellectual property. Altogen Labs works with pharmaceutical, biotechnology, and academic organizations worldwide to evaluate therapeutic candidates in validated in vivo models and generate data for efficacy, safety, PK/PD, pathology, and IND-supporting studies. The company provides integrated preclinical services from early-stage evaluation through advanced development.
Contact Information: Altogen Labs | Email: info@altogenlabs.com | Web: altogenlabs.com